Recent news on Topotecan

Hana Biosciences Announces First Quarter 2007 Results  -  May 14, 2007
Primenewswire (press release),Optisomal Topotecan remains on track to enter Phase 1 clinical trials in the second half of 2007. * Menadione preclinical work is ongoing.

Hana Biosciences 4Q Loss Widens  -  Mar 30, 2007
Houston Chronicle,Over the year, the company acquired licenses to three cancer therapies Marqibo, Alocrest, and Sphingosome Encapsulated Topotecan.

Sister Irene's doing it her way  -  Apr 7, 2007
The Union Leader,...(The real name of the drug is Topotecan, but the children's pronunciation delights her every time.) First-grade teacher Caryl Pawlusiak said her students

INEX Releases 2006 Operating Results and Announces 2007 Corporate ...  -  Apr 4, 2007
Drug Newswire (press release),...targeted chemotherapy products - Marqibo(R) (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan).

Hana Biosciences Announces Fourth Quarter and Year-End 2006 Results  -  Mar 29, 2007
Primenewswire (press release),...agents that utilize sphingosome encapsulation as the drug delivery platform: Marqibo(r), Alocrest(tm) and Sphingosome Encapsulated Topotecan.

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Feb 6, 2007
PharmaLive.com (press release),...sensitive small cell lung cancer are a variety of single agent and combination regimens including topotecan, cyclophosphamide, doxorubicin, vincristine,

Chemotherapy resistance and oncogene expression in non–small cell ...  -  Jan 31, 2007
The Journal of Thoracic and Cardiovascular SurgeryMore intermediate plus extreme chemotherapy resistances occurred in aneuploid tumors to etoposide (53% vs 36%, P = .0002) and topotecan (48% vs 36%,

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Jan 30, 2007
PipelineReview.com (press release),The current standards of care in treating platinum-resistant ovarian cancer are a variety of single agent and combination regimens including topotecan,

Telik Drug Disappoints  -  Dec 26, 2006
TheStreet.comA 440-patient study comparing Telcyta with liposomal doxorubicin or topotecan fell short of its main target of demonstrating a statistically significant

Telik?s Shares Take Tumble On Telcyta Phase III Failures  -  Dec 27, 2006
Therapeutics Daily (subscription) (press release),A 440-patient trial called ASSIST-1 with Telcyta (canfosfamide) tested the compound as compared to control agents liposomal doxorubicin or topotecan in the

Dendrimers Improve Cancer Drug Uptake and Antitumor Activity  -  Jan 15, 2007
Nanotechwire.com,...of three promising anticancer agents belonging to the camptothecin family, which also includes the widely used drugs topotecan and irinotecan.

Telik share price plummets after cancer drug failure  -  Jan 3, 2007
DrugResearcher.com,...trial tested Telcyta against ovarian cancer and again, did not improve survival compared to the control therapies (liposomal doxorubicin or topotecan).

Telik collapses as cancer drug fails three Phase III trials  -  Jan 1, 2007
Pharma Times (subscription),Telcyta did not achieve the primary endpoint of improved overall survival when compared to liposomal doxorubicin or topotecan.

Telik Reports Preliminary Results On ASSIST-1, ASSIST-2 And ASSIST ...  -  Dec 29, 2006
Medical News Today (press release),...randomized study designed to evaluate TELCYTA as compared to the active control agents liposomal doxorubicin or topotecan in the third-line therapy of

Cancer drug failure sinks Telik shares  -  Dec 27, 2006
Los Angeles Times,...cancer trial tested patients who had failed other treatments, some of whom received Telcyta and some received the drugs liposomal doxorubicin or topotecan.

Cancer Drug Fails Test, and the Company’s Stock Tumbles  -  Dec 26, 2006
New York Times,...trial tested patients who had failed several previous treatments: some received Telcyta and some received the agents liposomal doxorubicin or topotecan.

Telik's leading cancer drug suffers setback  -  Dec 26, 2006
MarketWatchIt did the same in an Assist-1 trial evaluating performance in comparison to liposomal doxorubicin or topotecan as a third-line therapy for platinum

Telik Thrashed After Cancer Drug Flunks Trials  -  Dec 26, 2006
Smartmoney.comThe Assist-1 trial was designed to evaluate Telcyta as compared to the active-control agents liposomal doxorubicin or topotecan in the third-line therapy of

Telik Shares Plummeted Following News Of Cancer Drug Failures  -  Dec 26, 2006
Trading Markets,The company noted that the clinical results from ASSIST-1 trial of TELCYTA as compared to the active control agents liposome doxorubicin or topotecan,

Telik cancer drug falls short in trials  -  Dec 26, 2006
United Press International...a 440-patient study comparing Telcyta to liposomal doxorubicin or topotecan as a third-line therapy for patients with platinum-resistant ovarian cancer,

Pharma Sector: Few Newsmakers Of The Week - Eli Lilly, Bristol ...  -  Dec 29, 2006
Trading Markets,The ASSIST-1 trial, a 440 patient multinational, randomized study, compared telcyta to chemotherapy drug topotecan in treating ovarian cancer.

Telik Drug Disappoints  -  26 Dec 2006
TheStreet.comA 440-patient study comparing Telcyta with liposomal doxorubicin or topotecan fell short of its main target of demonstrating a statistically significant

Hycamtin® (topotecan HCl) Indication Expanded To Include Treatment ...  -  Dec 8, 2006
Medical News Today (press release),GlaxoSmithKline plc announced today that the European Medicines Agency (EMEA) has granted Marketing Authorisation for HYCAMTIN® (topotecan HCl) in

Hycamtin(R) (Topotecan HCl) Indication Expanded To Include ...  -  Dec 1, 2006
DG NewsRandomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol.

Hycamtin® Improves Survival in Patients with Relapsed Small Cell ...  -  Dec 6, 2006
Cancer Consultants (press release),Phase III Trial Comparing Supportive Care Alone with Supportive Care with Oral Topotecan in Patients with Relapsed Small-cell Lung Cancer.

GSK score EU nod for combo cervical cancer drug  -  Dec 4, 2006
Pharma Times (subscription),GlaxoSmithKline has been boosted by the news that the European Medicines Agency has granted marketing approval for the firm's Hycamtin (topotecan) to be

Doxil® and Paraplatin® Effective for Recurrent Ovarian Cancer  -  Nov 30, 2006
Cancer Consultants (press release),The data also indicates that Doxil is more effective and more cost effective than Hycamtin® (topotecan) in patients with platinum-sensitive advanced ovarian

Multicell drug candidate guides immune system to destroy virally ...  -  Nov 27, 2006
DrugResearcher.com,At the moment, cervical cancer is commonly treated with either cisplatin or topotecan often in conjunction with either radiotherapy or hysterectomy.

Pharmion Acquires Cabrellis Pharmaceuticals  -  Dec 4, 2006
Pharmaceutical Online (press release),Topotecan (Hycamtin: GlaxoSmithKline), the only single-agent chemotherapeutic agent approved in the US for the treatment of SCLC sensitive disease after

St. Jude eye tumor work promising  Nov 7, 2006
St. Jude scientists later treated mice with retinoblastoma by pairing nutlin-3 with topotecan, another experimental drug. Tumors ... -commercialappeal.com (subscription), Sonus Pharmaceuticals Updates Corporate Progress and Reports Third ...  Nov 8, 2006
2006. TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. ... -Business Wire (press release), Breakthrough In Eye Cancer Treatment  Nov 6, 2006
Jude team modified the treatment by combining this molecule with topotecan, a drug also being investigated in the treatment of retinoblastoma. ... -Medical News Today (press release), New Treatment Strategy for Retinoblastoma Arises from Mechanistic ...  Nov 1, 2006
Rather, p53 is inactivated, which points to nutlin-3 and topotecan as possibly effective treatment, scientists in the US and Europe report. . ... -Cancerpage.com, Drug combo for childhood eye cancer developed  Nov 1, 2006
The two drugs, nutlin-3 which was originally developed by the US drug company Roche Pharmaceuticals and topotecan, block the action of a molecule called MDMX ... -Scientific American St. Jude Announces Breakthrough In Eye Cancer Treatment  Nov 2, 2006
After demonstrating the effectiveness of locally applied nutlin-3, the team combined it with topotecan, a drug also being investigated in the treatment of ... -Medical News Today (press release), Gene profiling boosts tailored chemotherapy  Oct 22, 2006
...laboratory tests. These cells have well-recorded responses to various chemotherapy agents, such as Topotecan and Paclitaxel. A statistical ... -New Scientist (subscription), Foro de Shell Security - Seguridad informática  Oct 26, 2006
Fo topotecan many of the B-cell NHL subtypes, the pattern of growth toprol xl and cell size may be important determinants of tumor toprol-xl aggressiveness. ... -Shell Security, Test helps guide cancer treatment, US study shows  Oct 22, 2006
...other drugs. The Duke team looked at older and less-specific cancer drugs such as paclitaxel, topotecan and 5-fluorouracil. The ... -Reuters Indena steps up efforts in "natural drug" market  Oct 16, 2006
...development. The first one, IDN 5404, is an API selected for its action against tumour resistance to cisplatin and topotecan. The ... -In-PharmaTechnologist.com, Meeting Highlights From The Committee For Medicinal Products For ...  Oct 20, 2006
Hycamtin (topotecan), from SmithKline Beecham Plc, received a positive opinion to include treatment, in combination with cisplatin, of patients with ... -Medical News Today (press release), Committee for Medicinal Products for Human Use Post-authorisation ...  Oct 20, 2006
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB ... -PharmaLive.com (press release), Central nervous system lymphoma responded to topotecan salvage ...  Sep 14, 2006
Primary central nervous system lymphoma (PCNSL) patients responded to topotecan salvage therapy with acceptable toxicity. According ... -Therapeutics Daily (subscription)

Addition of Gemzar® to Paraplatin® Improves Progression-Free ...  Sep 20, 2006
...the palliative treatment of recurrent ovarian cancer including: Doxil® (pegylated doxorubicin), Thalomid® (thalidomide), Hycamptin® (topotecan) and Navelbine ... -Cancer Consultants

Ovarian cancer: platinum-based therapy still the gold standard  Sep 11, 2006
There are also other drugs such as Eli Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan) and Ortho Biotech/Schering Plough's Doxil/Caelyx ... -Pharmaceutical Business Review

Cancer victim Laura pins hope on new drug  Aug 28, 2006
Dr Glaser said the drug, Topotecan, will be used in conjunction with drugs already established in the treatment of the rare cancer. ... -This is Bradford

Doxil®/Gemzar® Confirmed Effective for Recurrent Ovarian Cancer  Sep 1, 2006
The data also indicates that Doxil is more effective and more cost effective than Hycamtin® (topotecan) in patients with platinum-sensitive advanced ovarian ... -Cancer Consultants

Hycamtin® (topotecan HCl) Indication Expanded To Include Treatment ...  -  Dec 8, 2006
Medical News Today (press release),GlaxoSmithKline plc announced today that the European Medicines Agency (EMEA) has granted Marketing Authorisation for HYCAMTIN® (topotecan HCl) in

Hycamtin(R) (Topotecan HCl) Indication Expanded To Include ...  -  Dec 1, 2006
DG NewsRandomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol.

Hycamtin® Improves Survival in Patients with Relapsed Small Cell ...  -  Dec 6, 2006
Cancer Consultants (press release),Phase III Trial Comparing Supportive Care Alone with Supportive Care with Oral Topotecan in Patients with Relapsed Small-cell Lung Cancer.

GSK score EU nod for combo cervical cancer drug  -  Dec 4, 2006
Pharma Times (subscription),GlaxoSmithKline has been boosted by the news that the European Medicines Agency has granted marketing approval for the firm's Hycamtin (topotecan) to be

Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to ...  -  Nov 15, 2006
Earthtimes.orgTopotecan(Hycamtin(TM): GlaxoSmithKline), the only single-agent chemotherapeutic agentapproved in the US for the treatment of SCLC sensitive disease after

Doxil® and Paraplatin® Effective for Recurrent Ovarian Cancer  -  Nov 30, 2006
Cancer Consultants (press release),The data also indicates that Doxil is more effective and more cost effective than Hycamtin® (topotecan) in patients with platinum-sensitive advanced ovarian

Multicell drug candidate guides immune system to destroy virally ...  -  Nov 27, 2006
DrugResearcher.com,At the moment, cervical cancer is commonly treated with either cisplatin or topotecan often in conjunction with either radiotherapy or hysterectomy.

Sonus Pharmaceuticals to Present at Lazard Capital Markets Third ...  -  Nov 22, 2006
PharmaLive.com (press release),TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. Preclinical data suggest that

Cancer victim Laura pins hope on new drug  29 Aug 2006
Dr Glaser said the drug, Topotecan, will be used in conjunction with drugs already established in the treatment of the rare cancer. ... -This is Bradford

Topotecan Not Recommended for Ovarian Cancer  Aug 1, 2006
1 (HealthDay News) -- When added to standard first-line chemotherapy treatment for ovarian cancer, the drug topotecan doesn't increase patient survival and is ... -Forbes

Addition Of Topotecan To Standard Treatment Is Not Recommended For ...  Aug 4, 2006
The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended ... -Medical News Today

Third Chemo Drug No Help for Ovarian Cancer  Aug 2, 2006
Summary: Adding the drug topotecan to standard chemotherapy for advanced ovarian cancer does not help women with the disease live longer, German researchers say ... -ACS News Center

Hana Biosciences Initiates Phase I Clinical Trial of a Targeted ...  Aug 3, 2006
Vincristine, vinorelbine and topotecan are approved cancer therapies which have been selected for sphingosomal formulation specifically for their ability to ... -Business Wire

Addition of Hycamtin® to Standard Therapy Does Not Improve ...  Aug 3, 2006
According to results recently published in the Journal of the National Cancer Institute, the addition of Hycamtin® (topotecan) to the standard chemotherapy ... -Cancer Consultants

Cabrellis' $27.5M Series A To Fund Three SCLC Trials  Aug 7, 2006
The first, under way at several sites in the US, is assessing the safety and efficacy of Calsed compared to topotecan in the second-line treatment of patients ... -BioWorld Online

Triple-Chemo Regimen No Improvement in Ovarian Cancer  Aug 1, 2006
1 -- For women with advanced ovarian cancer, adding Hycamtin (topotecan) to a standard two-drug chemotherapy regimen does not improve survival, found ... -MedPage Today

Cabrellis raises $28 million to support cancer drug development  Aug 8, 2006
The first trial, designed to assess the safety and efficacy of Calsed in reference to topotecan in the second-line treatment of patients with SCLC who ... -PharmaLeader

INEX Releases Second Quarter 2006 Operating Results  Aug 3, 2006
...for Marqibo in 2006 and initiating phase 1 clinical trials for INX-0125 (sphingosomal vinorelbine) in 2006 and for INX-0076 (sphingosomal topotecan) in 2007. ... -Yahoo! News

Cabrellis Pharmaceuticals Raises $27.5 Million in Series A Funding  Aug 7, 2006
The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who ... -PharmaLive.com

Insert Therapeutics Treats First Patient with Nano-Engineered Anti ...  Jul 19, 2006
Although analogues of camptothecin (eg, irinotecan and topotecan) continue to realize nearly $1 billion in worldwide sales annually, camptothecin itself has ... -AZoNano.com

Arrowhead Research Subsidiary, Insert Therapeutics, Treats First ...  Jul 19, 2006
Although analogues of camptothecin(eg, irinotecan and topotecan) continue to realize nearly $1 billionin worldwide sales annually, camptothecin itself has not ... -Finanzen.net

Agreement to scale up new high potency molecules  Jul 19, 2006
...the process. IDN 5404 is a highly potent API selected for its action against tumor resistance to cisplatin and topotecan. IDN 5243 ... -Laboratory Talk

FDA Approves New Combination Therapy for Cervical Cancer  Jun 21, 2006
Summary: The US Food and Drug Administration has approved the use of topotecan (Hycamtin) along with cisplatin for the treatment of women who have very ... -ACS News Center

Inex Revises Plan of Arrangement to Spin Out Tekmira ...  Jul 11, 2006
The three products in the Targeted Chemotherapy pipeline, Marqibo, INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan), have been ... -Yahoo! News

Oral Hycamtin® May Offer Alternative for Recurrent Non–small ...  Jun 28, 2006
According to results recently published in the Journal of Clinical Oncology, the oral chemotherapy agent Hycamtin® (topotecan) may provide an effective ... -Cancer Consultants

Oral Hycamtin® May Offer Oral Therapy for Recurrent Non–Small ...  Jun 30, 2006
Researchers from Europe, South Africa and Canada have reported that oral Hycamtin (topotecan) and intravenous Taxotere® (docetaxel) are of equal benefit for ... -Cancer Consultants

Researchers Stop Tumor Growth in Mice, Ready to Join Others in ...  Jul 5, 2006
This week it approved a combination of Hycamtin (topotecan hydrochloride) and cisplatin for use as the first drug treatment for women with late-stage cancer of ... -SeniorJournal.com

Doxil Receives Full FDA Approval  Jun 30, 2006
...phase III study, 239 patients with recurrent epithelial ovarian cancer received Doxil® 50mg/m2 every 28 days and 235 received Hycamtin® (topotecan HCI) 1.5mg ... -Cancer Consultants

Hycamtin® Approved for Advanced Cervical Cancer  Jun 30, 2006
GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan) has received FDA approval for an expanded indication to include treatment of recurrent cervical ... -Cancer Consultants

Supplemental New Drug Application Accepted for Hycamtin® in ...  Jun 30, 2006
...and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan HCL) for ... -Cancer Consultants



CA-125 May Not Be Reliable Marker for Response to Doxil® In ...  May 3, 2006
A previous clinical trial was conducted to directly compare the chemotherapy agents Doxil and topotecan in women with recurrent ovarian cancer. ... - Cancer Consultants

Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ...  May 8, 2006
...-- Sphingosome Encapsulated Vinorelbine Targeted to Start Clinical Trials in 2006, and Sphingosome Encapsulated Topotecan in 2007. ... - Genetic Engineering News

Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement  May 8, 2006
...worldwide license to develop and commercialize Marqibo(TM) (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan ... - Yahoo! News

Hycamtin® More Convenient than Etoposide in Small Cell Lung ...  May 5, 2006
According to results recently published in the Journal of Clinical Oncology, the chemotherapy agent Hycamtin® (topotecan) taken orally in the pill form plus ... - Cancer Consultants

Genetic insights may explain retinal growth, eye cancer  May 10, 2006
Subsequently, the team used these models to demonstrate that a combination of topotecan and carboplatin were superior to the current treatment being used to ... - innovations report

Hana Biosciences Reports First Quarter 2006 Results  May 4, 2006
The three candidates are known as Marqibo(R) (vincristine sulfate) Liposomes Injection, Vinorelbine Liposomes Injection, and Topotecan Liposomes Injection. ... - Genetic Engineering News

Lung cancer CPT-11/SN-38 resistance marked by ABCG2 expression  Apr 20, 2006
..."Because H23/SN-38 cells show cross resistance to certain anticancer drugs, such as topotecan, etoposide, doxorubicin and mitoxantrone, ... - Therapeutics Daily (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional